Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
The four companies will share knowledge on packaging technologies to reduce environmental burden, such as blister packs made of biomass-based plastic instead of petroleum-derived plastic, compact packaging, recycled packaging materials, and recyclable packaging materials.
The company said it would acquire Nimbus Therapeutics’ drug being developed to treat autoimmune conditions such as psoriasis in up to $6 billion deal.
Japanese company Takeda’s dengue vaccine was authorized for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.
The FDA granted priority review to Takeda’s Biologics License Application for TAK-003, a dengue vaccine candidate. The vaccine to date is only approved for use in Indonesia.
The top pharma companies in 2021 continued to be engaged in creating vaccines and therapeutics, and the investments in R&D led to greater revenue and earnings.
With recent years of acquisitions and divestitures in the rearview, Takeda can focus on what matters most: growing its brands.
inch Therapeutics is slashing its headcount by around 37% and suspending its planned Phase I study in autism one week after Takeda withdrew from its multi-year collaboration, the company announced Thursday.
While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.
With an investment valued at up to $1.1 billion, Merck is diving back into Alzheimer’s research through a collaboration with Cerevance.